Physician profile
Michael C Bravoco
NPI 1699747311
$483.76
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $85.83 · 2021: $42.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $150.56 | 2019-2020 | |
| Lupin INC. | $55.96 | 2019 | |
| Hologic Sales and Service, LLC | $51.08 | 2019 | |
| Duchesnay USA Incorporated | $40.34 | 2019 | |
| Covidien LP | $32.32 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.82 | 2019-2020 | |
| Astellas Pharma US INC | $28.16 | 2019 | |
| Smith+Nephew, INC. | $27.50 | 2021 | |
| Mayne Pharma Commercial LLC | $14.52 | 2021 | |
| Allergan, INC. | $14.50 | 2019 | |
| Merck Sharp & Dohme LLC | $14.50 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.02 | 2019 | |
| Therapeuticsmd, INC. | $11.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bravoco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.